A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis

Summary

The objective of this study is assessing the efficacy and safety of brodalumab in Chinese subjects with moderate to severe plaque psoriasis.

Timeline

Start

2021-01

Primary completion

2022-02

Completion

2022-11

Outcome

Outcome not reported

Stopped (Enrollment): “Due to the reconsideration of KHK4827's business in China, it. was decided to withdraw this clinical trial prior to enrollment of first participant.”

Drugs

Indications